gms | German Medical Science

44. Kongress der Deutschen Gesellschaft für Rheumatologie, 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

31.08. - 03.09.2016, Frankfurt am Main

Two subsets of giant cell arteritis characterized by the absence or presence of spondyloarthritis or its associated diseases

Meeting Abstract

  • Diana Ernst - Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
  • Niklas Baerlecken - Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
  • Reinhold E. Schmidt - Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
  • Torsten Witte - Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Frankfurt am Main, 31.08.-03.09.2016. Düsseldorf: German Medical Science GMS Publishing House; 2016. DocVK.15

doi: 10.3205/16dgrh234, urn:nbn:de:0183-16dgrh2340

Published: August 29, 2016

© 2016 Ernst et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Background: Whilst large vessel vasculitis (LVV) predominantly occurs in isolation, associations with other infectious and non-infectious diseases have been reported. Limited data describing associations with various autoimmune diseases, including spondyloarthritis exists. The aim of this study was to characterize the association of LVV and spondyloarthritis or its associated diseases (SpAD).

Methods: A single centre, retrospective study of patients ≥50yrs with first presentation LVV between 01.06.2008-01.06.2015 was performed. Patients were categorized according to SpAD, other autoimmune disease (AI) or controls. Clinical, laboratory and imaging findings were compared. Kaplan-Meyer survival analysis, with relapse taken as the primary end-point, was performed.

Results: LVV was confirmed in 62 pts, of who 16/62 (26%) had SpAD. In these patients, LVV presented earlier (59.2 SpAD vs. 68.1 AI and 70.3yrs Controls; p=0.01) and occurred predominantly in spring compared to autumn and winter in non-SpAD patients, was associated with more centralised pattern of distribution (p=0.05) and was more likely to exhibit a refractory course (p=0.05). Overall relapse rates were similar across groups. Smoking-status influenced age of onset in all groups, being associated with earlier onset.

Conclusion: A clear association between LVV and SpAD exists. LVV associated with SpAD has a particular phenotype characterised by earlier onset, thorax-limited disease and increased risk of a refractory course. Given on-going LVV treatment trials further genetic and pathophysiological characterization appears warranted, to evaluate potential variation in treatment response and optimize future care.